Innovative Therapies in Giant Cell Arteritis

This chapter explores the critical role of screening for opportunistic infections in patients on immunosuppressive therapies and compares the efficacy of upadacitinib and tocilizumab in treating giant cell arteritis. It also highlights the differences in treatment guidelines between Europe and America, and the broader implications of JAK inhibitors in managing various immune-mediated diseases.